dr claes wilhelmsson ta portfolio page 1 a r&d organisation & therapy area update executive director and process discovery areas development operations target identifi cation hit lead cd prenom ination develop ment for launch concept testing optimis ation product maint life cycle support 2 contribute to doubling the value of in all major markets within first year reduce time from 6 years double project success rate output 15 per deliver 3 medically important commercially attractive products quantitative targets gi cv respiratory oncology pain control cns infection 10 top market position share serious hospital high growth ambitions arimidex oxis accolate atacand losec pulmicort seroquel diprivan zestril casodex nolvadex seloken tenormin zoladex xylocaine merrem zomig plendil rhinocort prilosec crestor esomeprazole thrombin inhibitor faslodex iressa viozan symbicort strong pipeline tomorrow
